Preventive Medicine Pioneer
Biological E supplies most of the essential and life saving drugs to Central and state government hospitals, PSUs, the Indian armed forces and the domestic retail market.
Business: Manufacturer of vaccines, formulations and APIs
CEO: Dr Vijay Kumar Datla
Biotech Revenue: Rs 28.23 crore
Start-up Year: 1953
Address: 18/3, Azamabad, Hyderabad – 500 020
Tel.: 91-40-27617835, 27615134
Biological E (BE) was established over 50 years ago. It is the first private sector biological products company in India and the first pharmaceuticals company in South India. BE is also the pioneer in preventive medicine. Biological E supplies most of the essential and life saving drugs to Central and state government hospitals, public sector undertakings, the Indian armed forces and the domestic retail market. Its international division provides global-access to high quality innovative products and caters to the health and well being of people worldwide.
Biological E has structured its business into three major areas – biologics, pharma and public markets. The company exports many of its products to Asia, the CIS countries, the US and Latin American countries.
Beparine and Neo-Hepatex have proved to be blockbuster
molecules for the company and it also produces paediatric vaccines like DPT, TT
Biological E is investing approximately $ 50 million towards the development and expansion of infrastructure. State-of-the-art equipment is being installed in all locations that will meet the US FDA and European MEA standards in manufacturing, quality control and pre-clinical activities. As per the regulatory requirements it has specialized suites for different manufacturing activities. Dedicated laboratories have also been provided to carry out testing of the quality control setup.
Several projects are underway to strengthen and expand Biological E's drive to internationalize its business. One of these is the compact and well-maintained production facility to manufacture APIs in Pattancheru, which has ample scope for future expansion. Another project underway is the modern biotech facility, with an investment of Rs 100 crore, in the Genome Valley, Andhra Pradesh. It has taken up this state-of-the-art technology project to produce a new generation of vaccines, focused on reaching out to international markets. This project complies strictly with the WHO and US FDA GMP guidelines.
BE features a broad range of promising projects in various stages of development. Some of these are the Haemophilus type B conjugate vaccine and DTwP-HBV-HIB combination. The DTwP-HBV combination are currently undergoing Phase-III human clinical trials and the meningitis vaccine is under research and development in which polysaccharides developed from serotypes A, C, W & Y will be mixed to formulate the vaccine. Already serotype A and C polysaccharides have been standardized.